Get involved in research

Below is a list of current Australian researchers recruiting for participants. Please direct any queries about specific studies to the contact of the study.

You can search for a study by state or select All States for those studies which are national.

If you have any questions regarding content on this page or want to modify your study once submitted please email research@dementia.org.au

The Markers in Neurpsychiatric Disorders (MiND) Study is exploring blood biomarkers to improve early and timely diagnosis for people with cognitive, psychiatric and neurological symptoms. The ultimate goal of this research is to lead to routine, clinically available tests that would improve outcomes for people with cognitive, psychiatric and/or neurological symptoms, their families, clinicians…

Participating states:
All States
Occurring dates:
to

The SAMe Study is a research project investigating a potential treatment for Alzheimer's disease, called S-Adenosyl Methionine, or more commonly known as “SAMe”. It is thought that Alzheimer's disease may be caused by the toxic build-up of proteins in the brain such as tau and amyloid-beta. This study is looking at whether taking SAMe once a day will reduce tau protein levels.

You or…

Participating states:
Western Australia, Victoria
Occurring dates:
to

After receiving a diagnosis of dementia it is very important that individuals and families have access to support and advice at this time, to help people regain control, plan for the future and carry on living a life that is meaningful to them. This study aims to test a new online training and support group for people in the early stages of dementia and e-learning programme for care partners…

Participating states:
New South Wales
Occurring dates:
to

The aim of this study is to evaluate the effect of JNJ-63733657, which is a monoclonal anti-tau antibody to prevent collection of tau in the brain by clearing it from the brain. The study will investigate whether JNJ-63733657 can slow cognitive decline in participants with Early Alzheimer’s disease with evidence of elevated brain tau (T+) and assess its safety and tolerability.

Who can…

Participating states:
Western Australia
Occurring dates:
to

This is a Phase 3 study to test whether treatment with BAN2401 prevents cognitive decline and reduces brain amyloid accumulation, which is considered as one of the causes of Alzheimer’s disease. The changes in the amount of amyloid and tau in the brain will be monitored to determine the efficacy of the investigational medication.

Who can be involved?

  • Male or female, aged…
Participating states:
Western Australia
Occurring dates:
to

Currently there are no approved treatments for fronto-temporal dementia. The main purpose of this research project is to look at whether the trial drug, sodium selenate decreases the rate of brain shrinkage in patients with fronto-temporal dementia. The research project will also look into the effect of sodium selenate on brain function and markers of disease measured on brain scans, in blood…

Participating states:
New South Wales, Victoria
Occurring dates:
to

This project seeks to identify whether eye and brain tests can serve as early diagnostic markers for Alzheimer’s disease and dementia. We will evaluate the potential correlation of retinal, structural and functional changes within the eye to brain changes including cognitive decline and progression over a period of five years.

Participants must meet the following criteria:

Participating states:
New South Wales
Occurring dates:
to

While it is well known that people with Parkinson’s disease (PD) experience problems with their movement, it is lesser known that around 80% of people with PD develop dementia. Research conducted at Johns Hopkins University in the U.S.A. has found that low doses of the anti-epileptic drug levetiracetam can reduce memory problems in people prone to Alzheimer’s disease.

The aim of this…

Participating states:
Queensland
Occurring dates:
to

The ACT-AD trial is evaluating if a new investigational drug (ATH-1017) is safe and effective in improving symptoms of mild to moderate Alzheimer’s disease. ATH-1017 is designed to boost a repair and regenerative pathway for brain cells, promoting brain health and function. ATH-1017 represents a new approach to treat Alzheimer’s disease, potentially targeting the root cause of memory decline…

Participating states:
New South Wales, Western Australia, Victoria
Occurring dates:

Hearing loss is a modifiable risk factor for dementia, yet approximately 83% of people or more with hearing loss do not use hearing devices.

This research project aims to investigate the effect of hearing aid and cochlear implant use on cognition in older adults, controlling for other dementia risk factors. These effects have not yet been examined in a longitudinal study that…

Participating states:
Victoria
Occurring dates:
to